Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
PNU 37883 is an inhibitor of ATP-sensitive potassium (KATP) channels.1 It inhibits sulfonylurea receptor 2B (SUR2B) linked to ATP-sensitive potassium channel Kir6.2 (SUR2B/Kir6.2) and SUR2B/Kir6.1 (IC50s = 15.2 and 6 µM, respectively) and SUR1/Kir6.2 and SUR2A/Kir6.2 to a lesser extent at 100 µM. PNU 37883 (0.1 and 0.3 µM) inhibits relaxation of isolated rat middle meningeal arteries induced by pinacidil (Item No. 15416), levcromakalim, or P1075 (Item No. 21849).2 It increases kallikrein secretion from microdissected connecting tubules isolated from normotensive and spontaneously hypertensive rats.3 PNU 37883 (15 mg/kg) increases sodium excretion and does not affect potassium excretion or glomerular filtration rate in saline-loaded rats.4
WARNING This product is not for human or veterinary use.
1. Different molecular sites of action for the KATP channel inhibitors, PNU-
2. KATP channel expression and pharmacological in vivo and in vitro studies of the KATP channel blocker PNU-
3. Potassium-
4. Effects of a K+ channel blocker on glomerular filtration rate and electrolyte excretion in conscious rats. J. Pharmacol. Exp. Ther. 273(3), 1375-1381 (1995).